CONTACT US

CHDI Foundation extends collaboration with IRBM to accelerate development of Huntington’s disease therapeutics

Pomezia, Italy, November 19th 2018 – IRBM, a global contract research organization (CRO), has strengthened its position in neurodegenerative disease research following an extension of its long-standing collaboration with CHDI Foundation, a nonprofit biomedical research organization exclusively dedicated to collaboratively developing therapeutics that substantially improve the lives of those affected by Huntington’s disease (HD).

Continue Reading

Comments (0) Home, All News, Press Release

Read more

IRBM signs collaboration agreement with Merck & Co., Inc, Kenilworth, NJ, USA to advance peptide therapeutics

4th September 2018

Pomezia, Italy – IRBM, today announced a new agreement in the peptide therapeutics area with Merck & Co. Inc., Kenilworth NJ USA, known as MSD outside the United States and Canada, continuing their long-standing history of collaboration that began in 2010.

Continue Reading

Comments (0) Home, All News, Press Release

Read more

IRBM has entered into a license agreement with iPS Academia Japan, Inc.

Pomezia, Italy, June 19, 2018 – IRBM will be providing services using human induced pluripotent stem cells (hiPSCs) based on the iPS cell-related patents that have been sublicensed to iPS Academia Japan by Kyoto University. Continue Reading

Comments (0) All News, Press Release

Read more

IRBM continues global growth with two new appointments

IRBM continues global growth with two new appointments

Pomezia, Italy, May 31, 2018 –  IRBM, a global Contract Research Organization, has recruited two new members of staff as part of its global growth strategy. Carlo Toniatti, M.D., Ph.D., has been appointed as the Chief Scientific Officer, bringing more than two decades of drug development and discovery experience to the role where he will oversee scientific strategy, and Heidi Kingdon-Jones has been recruited as the Global VP of Sales and Marketing, to drive forward IRBM’s continued global expansion. Continue Reading

Comments (0) All News, Press Release

Read more